스페인의 심혈관 기기 시장 : 점유율 분석, 산업 동향, 통계, 성장 예측(2025-2030년)

The Spain cardiovascular devices market size stands at USD 1.55 billion in 2025 and is projected to reach USD 2.01 billion by 2030, yielding a compound annual growth rate (CAGR) of 5.39% for 2025-2030.

This growth reflects the government's effort to modernize public hospital equipment while maintaining overall budget discipline. Therapeutic and surgical devices command the largest Spain cardiovascular devices market share, whereas diagnostic and monitoring technologies are advancing faster as hospitals look to detect disease earlier and shorten inpatient stays. Manufacturers that bundle interventional hardware with digital monitoring services already benefit from broader recurring revenue streams. Meanwhile, accelerated investment by private cardiology networks lifts total demand and raises expectations for premium functionality, forcing suppliers to balance standardized offerings for public institutions with high-end solutions for private centers.

Spain Cardiovascular Devices Market Trends and Insights

National Cardiovascular Health Plan 2022-2029 Catalyzing Public Procurement

The plan allocates EUR 215 million for cardiovascular equipment modernization, accelerating replacement of aging imaging systems and catheterization labs. Standardized multi-year service contracts shorten bid cycles and guarantee training, which spurs volume-led growth for basic diagnostic platforms and value-driven demand for advanced technologies. Hospitals in underserved regions gain faster access to updated cardiac ultrasound, while flagship centers adopt fully integrated cath-lab suites. Suppliers with tiered portfolios capture share by meeting both ends of the performance spectrum.

Rapidly Ageing Population Expanding Device Demand

Citizens older than 65 generate a disproportionate share of cardiac procedures, and their clustering along the Mediterranean coastline creates utilization hotspots. Octogenarians are now the fastest-growing group for transcatheter valve replacement, prompting hospitals to revise scheduling and after-care protocols. Manufacturers have answered with smaller implants and longer battery life, which reduce rehospitalization risk. Hospitals that embrace geriatric-friendly technology often see utilization efficiencies that exceed regional averages.

Regional Tender Price Caps Compress Selling Prices

Autonomous communities such as Andalusia and Valencia enforce reference pricing 15-20% below direct-negotiation levels. The model prioritizes total cost of ownership, encouraging bids that bundle disposables, maintenance, and training. Mid-tier suppliers leave low-margin categories, consolidating share among firms that leverage scale. Hospitals could face fewer options in commodity segments if the current rules persist.

Other drivers and restraints analyzed in the detailed report include:

1. Reimbursement of TAVR & TMVR Accelerating Structural Heart Uptake
2. Expansion of Private Cardiology Networks Driving Premium Equipment
3. MDR Recertification Backlog Delaying Product Launches

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Therapeutic and surgical devices held 57.20% of Spain cardiovascular devices market share in 2024, buoyed by coronary stents and cardiac rhythm-management implants. Concurrently, the Spain cardiovascular devices market size for diagnostic and monitoring equipment is expected to grow at 6.03% CAGR through 2030 thanks to AI-guided imaging and national funding for early detection. Advanced transcatheter tools also shorten the life cycle of older surgical devices, shifting procurement toward minimally invasive systems that shorten hospital stays. Vendors that can package modular software licenses with core hardware capture incremental revenue without proportionally higher production costs.

Diagnostic adoption is no longer confined to academic centers. Fractional flow-reserve platforms and 3D echocardiography are penetrating regional hospitals, encouraged by standardized procurement guidelines under the National Cardiovascular Health Plan. At the same time, the therapeutic segment is intensifying its focus on structural heart interventions as payers recognize the cost benefits of shorter recovery times. Hospitals that achieve lower length-of-stay metrics through device innovation often qualify for performance-based financing, bolstering demand for the latest implants.

The Spain Cardiovascular Devices Market Report is Segmented by Device Type (Diagnostic & Monitoring Devices, Therapeutic & Surgical Devices), Indication (Coronary Artery Disease, Arrhythmia, Heart Failure, Valvular Heart Disease), End User (Hospitals, Home Care Settings, Others), and Geography (Spain). The Market Forecasts are Provided in Terms of Value (USD).

List of Companies Covered in this Report:

1. Medtronic
2. Boston Scientific
3. Abbott Laboratories
4. Edward Lifesciences
5. Koninklijke Philips
6. Siemens Healthineers
7. Terumo
8. BIOTRONIK
9. MicroPort
10. LivaNova
11. Cardinal Health
12. B. Braun
13. Meril Life Science
14. Acist Medical Systems
15. Getinge AB (Maquet)
16. W. L. Gore & Associates
17. Johnson & Johnson
18. Teleflex

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 National Cardiovascular Health Plan 2022-2029 Catalyzing Device Procurement in Public Hospitals
  • 4.2.2 Rapidly Ageing Spanish Population Expanding Cardiac Device Demand
  • 4.2.3 Reimbursement of TAVR & TMVR Accelerating Structural Heart Device Uptake
  • 4.2.4 Expansion of Private Cardiology Networks Driving High-End CRM & Imaging Equipment
  • 4.2.5 Rising Funds for Digital Cardiac Tele-monitoring Platforms
• 4.3 Market Restraints
  • 4.3.1 Regional Tender Price-Caps Compressing Average Selling Prices
  • 4.3.2 MDR Recertification Backlog Delaying New Product Launches in Spain
  • 4.3.3 Shortage of Interventional Cardiologists Outside Madrid & Catalonia Limiting Procedure Volumes
  • 4.3.4 120-Day Hospital Payment Cycles Impacting Vendor Cash-Flow
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Outlook
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts

• 5.1 By Device
  • 5.1.1 Diagnostic & Monitoring Devices
    • 5.1.1.1 ECG Systems
    • 5.1.1.2 Remote Cardiac Monitor
    • 5.1.1.3 Cardiac MRI
    • 5.1.1.4 Cardiac CT
    • 5.1.1.5 Echocardiography / Ultrasound
    • 5.1.1.6 Fractional Flow Reserve (FFR) Systems
  • 5.1.2 Therapeutic & Surgical Devices
    • 5.1.2.1 Coronary Stents
    • 5.1.2.1.1 Drug-Eluting Stents
    • 5.1.2.1.2 Bare-Metal Stents
    • 5.1.2.1.3 Bioresorbable Stents
    • 5.1.2.2 Catheters
    • 5.1.2.2.1 PTCA Balloon Catheters
    • 5.1.2.2.2 IVUS/OCT Catheters
    • 5.1.2.3 Cardiac Rhythm Management
    • 5.1.2.3.1 Pacemakers
    • 5.1.2.3.2 Implantable Cardioverter Defibrillators
    • 5.1.2.3.3 Cardiac Resynchronization Therapy Devices
    • 5.1.2.4 Heart Valves
    • 5.1.2.4.1 TAVR/TAVI
    • 5.1.2.4.2 Mechanical Valves
    • 5.1.2.4.3 Tissue/Bioprosthetic Valves
    • 5.1.2.5 Ventricular Assist Devices
    • 5.1.2.6 Artificial Hearts
    • 5.1.2.7 Grafts & Patches
    • 5.1.2.8 Other Cardiovascular Surgical Devices
• 5.2 By Indication
  • 5.2.1 Coronary Artery Disease
  • 5.2.2 Arrhythmia
  • 5.2.3 Heart Failure
  • 5.2.4 Valvular Heart Disease
• 5.3 By End User
  • 5.3.1 Hospitals
  • 5.3.2 Home care Settings
  • 5.3.3 Others

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles {(includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)}
  • 6.3.1 Medtronic Plc
  • 6.3.2 Boston Scientific Corporation
  • 6.3.3 Abbott Laboratories
  • 6.3.4 Edwards Lifesciences Corporation
  • 6.3.5 Philips Healthcare
  • 6.3.6 Siemens Healthineers AG
  • 6.3.7 Terumo Corporation
  • 6.3.8 Biotronik SE & Co. KG
  • 6.3.9 MicroPort Scientific Corporation
  • 6.3.10 LivaNova PLC
  • 6.3.11 Cardinal Health (Cordis)
  • 6.3.12 B. Braun Melsungen AG
  • 6.3.13 Meril Life Sciences Pvt Ltd
  • 6.3.14 Acist Medical Systems
  • 6.3.15 Getinge AB (Maquet)
  • 6.3.16 W. L. Gore & Associates
  • 6.3.17 Johnson & Johnson (Biosense Webster)
  • 6.3.18 Teleflex

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment